RxDoctor Payments Data

Elizabeth Mariano, MD

Hematology & Oncology · Middletown, CTNPI 1467659557

Payments from drug & device makers

$602in general payments, 2019–2025

Across 23 payments — averaging $26.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$122
  • Biogen$95
  • AstraZeneca$87
  • Genentech USA, Inc.$78
  • E.r. Squibb & Sons, L.L.C.$76
  • Merck$26
  • plus $116 from 7 others

What the payments were for

  • Food & beverage$57896%
  • Education$244%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$602 in reported general payments places this provider in the 30th percentile of 163 hematology & oncology providers in Connecticut.

See all hematology & oncology providers in Connecticut

Medicare billing

Part B allowed, 2024
$2,344,080
Medicare patients
351
Services billed
135,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate65$947,699
Lenalidomide13$259,312
ImbruvicaIbrutinib15$245,852
VenclextaVenetoclax16$234,561
IbrancePalbociclib13$211,923
PromactaEltrombopag Olamine15$126,206
XareltoRivaroxaban19$17,108
EliquisApixaban13$7,710
Anastrozole325$5,446
Exemestane15$1,993
Hydroxyurea80$1,861
Tamoxifen Citrate37$1,271
Letrozole33$1,133
Pregabalin11$272
Prednisone35$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$87$947,69965 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$13$245,85215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 163 hematology & oncology providers in Connecticut.

Other hematology & oncology in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →